Premium
Purging efficacy of ZnPcH 1 ‐based photodynamic therapy on chronic myeloid leukemia bone marrow
Author(s) -
HUANG H.,
CHEN Y.,
CHEN W.,
WU Y.
Publication year - 2011
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2011.01313.x
Subject(s) - myeloid leukemia , bone marrow , chronic myelogenous leukemia , ex vivo , cancer research , medicine , photodynamic therapy , leukemia , k562 cells , stem cell , haematopoiesis , immunology , pathology , in vivo , biology , chemistry , genetics , microbiology and biotechnology , organic chemistry
Summary Introduction: Ex vivo purging is an emerging technique for successful transplantation of autologous hematopoietic stem cells in the treatment of leukemia. Among them, photodynamic therapy (PDT) might be a promising modality. The objective of this study was to evaluate the purging efficacy of ex vivo PDT on chronic myeloid leukemia (CML). Methods: A new amphiphilic mono‐α‐substituted zinc (II) phthalocyanine (ZnPcH 1 ) was used as a PDT photosensitizer. Nest reverse transcription polymerase chain reaction (RT‐PCR) and real‐time quantitative PCR of BCR/ABL1 fusion gene remained positive were performed to determine the purging effects of ZnPcH 1 ‐PDT on the mixture of CML cell line K562 cells and normal bone marrow mononuclear cells (MNC) and on the CML cells from the bone marrow of patients with CML who had achieved complete hematology remission but whose BCR/ABL1 fusion genes remained positive. Results: CML cells exhibited higher susceptibility to ZnPcH 1 ‐PDT than normal granulocyte/macrophage progenitors. PDT could eliminate K562 cells from K562–normal MNC mixture and the residual BCR/ABL1 positive CML cells from the bone marrow of patients with CML. Conclusion: Our data suggest that ZnPcH 1 ‐PDT may be a useful modality for purging CML cells for autologous grafts.